Posted by Michael Wonder on 03 Nov 2021
TransThera receives fast track designation from FDA for its core product TT-00420 to treat cholangiocarcinoma
3 November 2021 - TransThera Sciences announced that the U.S. FDA has granted fast track designation to its phase II stage product TT-00420 for the treatment of patients with cholangiocarcinoma who have no standard treatment options.
TT-00420 is a spectrum selective kinase inhibitor that is found to show high potency to a variety of clinically identified FGFR2 mutations in preclinical experiments.
